Neurotechnology Market Report 2026

The neurotechnology market size has grown rapidly in recent years. It will grow from $17.34 billion in 2025 to $19.84 billion in 2026 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to advancements in medical imaging technologies, early adoption of neurostimulation therapies, increasing clinical research in neurology, rising prevalence of neurological disorders, technological progress in implantable devices.

The neurotechnology market size is expected to see rapid growth in the next few years. It will grow to $33.64 billion in 2030 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to growing investment in brain-computer interfaces, increasing demand for personalized neurological treatments, expanding use of ai-driven diagnostics, rising adoption of home-based neurotechnology, development of minimally invasive neurotherapies. Major trends in the forecast period include expansion of brain-computer interface solutions, rising adoption of non-invasive neurostimulation devices, increasing integration of neuroimaging in clinical diagnostics, growing demand for cognitive rehabilitation technologies, advancement in neurological implant materials.

The increased prevalence of neurological conditions is expected to drive the growth of the neurotechnology market in the coming years. Neurological conditions include any disorders or diseases that affect the brain, with common examples such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and migraines. Neurotechnology is increasingly utilized to diagnose and manage neurological disorders through various approaches, including brain imaging, neurostimulation, neurofeedback, and brain-computer interfaces. For instance, in October 2023, according to the World Federation of Neurology, a UK-based charity, reflecting a rapidly growing global health burden, neurological disorders have become the second-leading cause of death and the primary cause of disability worldwide, affecting more than 40 percent of the global population in 2023, with the number of individuals living with brain-related diseases projected to nearly double by 2050. Therefore, the rising prevalence of neurological conditions is contributing significantly to the expansion of the neurotechnology market going forward.

Major companies operating in the neurotechnology market are focusing on the development of advanced therapeutic solutions, such as endovascular brain-computer interfaces (BCIs), to improve cognitive function and restore mobility in patients with neurological impairments. An endovascular brain-computer interface enables direct access to neural signals through blood vessels, allowing enhanced interaction and treatment options for individuals with neurological disorders. For example, in April 2024, Synchron, a Sweden-based software company specializing in advanced synchronization technologies for seamless data integration and management, launched the Patient Registry for the Stentrode Brain Computer Interface. The Synchron Stentrode BCI technology is designed to decode brain signals and restore motor intent, enabling individuals with limited mobility to control digital devices without physical movement. Implanted using a minimally invasive endovascular procedure, the device wirelessly transmits motor intent from the brain, allowing patients with severe paralysis to regain a degree of independence. This innovative technology marks a major advancement in assistive solutions by enhancing everyday activities such as communication and access to essential services.

In May 2025, electroCore, a U.S.-based provider of non-invasive bioelectronic and neuromodulation therapies, completed the acquisition of NeuroMetrix for an undisclosed sum. Through this acquisition, electroCore aims to expand its neurotechnology portfolio and accelerate commercial growth by incorporating NeuroMetrix’s cloud-enabled wearable neuromodulation platform, strengthening its position in the chronic pain management segment. NeuroMetrix is a U.S.-based company offering neurotechnology solutions, including app-connected wearable neuromodulation devices for fibromyalgia and chronic pain, as well as diagnostic tools for neuropathic conditions.

Major companies operating in the neurotechnology market are General Electric, Medtronic PLC, Koninklijke Philips N.V., Shimadzu Corporation, Elekta AB, Natus Medical Incorporated, Abbott, Boston Scientific Corporation, Nihon Kohden Corporation, LivaNova PLC, Siemens Healthcare Private Limited, Hitachi Medical Corporation, Cochlear Limited, NeuroPace Inc., NeuroSigma Inc., NeuroMetrix Inc., NeuroSky Inc., NeuroVigil Inc., Neurotech Pharmaceuticals Inc., Neuralink, Synchron Inc., Blackrock Neurotech, Neuronetics Inc., Neurable Inc.

North America was the largest region in the neurotechnology market in 2025. Europe is expected to be the fastest-growing region in the neurotechnology market report during the forecast period. The regions covered in the neurotechnology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurotechnology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the neurotechnology market by increasing import costs for electronic components, sensors, and implant-grade materials, which form the backbone of advanced neurodiagnostic and neurostimulation systems. These additional costs primarily impact neurological implants, neurostimulation devices, and imaging systems, with significant effects in regions reliant on imported medical technologies such as Asia-Pacific and Europe. Clinical segments like epilepsy management devices, Parkinson's treatment systems, and cognitive disorder equipment face extended lead times and higher pricing. While the overall impact is negative, tariffs are prompting manufacturers to localize production, strengthen supply-chain resilience, and explore innovative low-cost component alternatives, creating limited positive opportunities for domestic suppliers.

The neurotechnology market research report is one of a series of new reports that provides neurotechnology market statistics, including neurotechnology industry global market size, regional shares, competitors with a neurotechnology market share, detailed neurotechnology market segments, market trends and opportunities, and any further data you may need to thrive in the neurotechnology industry. This neurotechnology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurotechnology involves the study of and interaction with the nervous system, including the brain and other components of the nervous system. It can be applied in clinical environments to influence brain or nervous system activity, particularly for therapeutic and rehabilitative purposes. Recent progress in neurotechnology has demonstrated potential in treating neurological disorders and improving cognitive function, establishing it as an important area of research and practical use.

The primary neurotechnology conditions include cognitive disorders, pain management, urinary and faecal incontinence, epilepsy, Parkinson’s disease, hearing conditions, sleep disorders, depression, and others. Cognitive disorders are characterized by a marked decline in an individual’s cognitive abilities to the extent that, without treatment, performing routine social activities becomes difficult. The different types include imaging modalities, neurostimulation, cranial surface measurement, neurological implants, and others, which are utilized by ambulatory surgical centers, hospitals, homecare settings, and other end users.

The neurotechnology market includes revenues earned by entities from neuro-rehabilitative treatment, heart rate variability, electroencephalography, and neurostimulation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The neurotechnology market consists of sales of brain-computer interfaces (BCIs), neurostimulation devices, virtual reality (VR), and prosthetic limb devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.